Navigation Links
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
Date:4/3/2012

al information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of April 4, 2012 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... 20, 2014 /CNW/ - The issue: Mylan Pharmaceuticals ULC Canada, ... of its Mylan-Nitro Spray 0.4 mg/metered dose due to the ... pump component. A missing "dip tube" could ... the patient. This defect may lead patients to believe they ... to access it. Not receiving nitroglycerin could place them at ...
(Date:9/19/2014)... , Sept. 19, 2014 Medical science ... relationships with key opinion leaders (KOLs) who can ... Despite the critical nature of the MSL function, ... including altering the landscape for creating and maintaining ... to research, the oversight responsibility for the MSL ...
(Date:9/19/2014)... NEW YORK , Sept. 19, 2014 ... claims against the board of directors of PDL BioPharma, ... ) concerning whether the board has breached its fiduciary ... On September 16, 2014, the Company disclosed: ... its independent registered accounting firm, Ernst & Young LLP ...
Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... Ill. , July 22 Sysmex America, Inc., ... information systems, today announced a partnership agreement with Medica Corporation ... to laboratories in North America , Mexico , ... Columbia . Sysmex America will be responsible for instrument ...
... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: ... capsules. This product was recently approved by the ... Pharma,s Abbreviated New Drug Application (ANDA). These tamsulosin ... 0.4 mg from Boehringer Ingelheim Pharmaceuticals, Inc. Tamsulosin ...
Cached Medicine Technology:Sysmex America and Medica Corporation Announce Distribution Partnership 2Sysmex America and Medica Corporation Announce Distribution Partnership 3Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Flomax® 2
(Date:9/20/2014)... (PRWEB) September 20, 2014 Villa del ... resort did not experience any damage in relation to ... and activities available. , Hurricane Odile struck Cabo San ... wind, rain and powerful surf conditions. Located on the ... Islands of Loreto experienced some heavy rain, but no ...
(Date:9/20/2014)... September 21, 2014 Increases in ... to greater waste treatment volumes. However, government regulations ... waste from landfill. According to IBISWorld industry analyst ... implemented strategies aimed at reducing the volume of ... recycled and recovered.” Still, a large proportion of ...
(Date:9/20/2014)... 2014 Ticket Down is a ... This popular ticket exchange is offering their customer appreciation ... 2015 schedule of tours is beginning to fill up. Many ... plans to hit the road, including 21-year-old pop superstar, Ariana ... “Honeymoon Tour,” which will take her to 25 cities across ...
(Date:9/20/2014)... Ticket Down is a reputable ... This popular ticket exchange is offering their customer appreciation promo ... that next step in the entertainment business. The 21-year-old from ... music and entertainment business, but is closing in on “Pop ... 1 album, will hit the road next year on the ...
(Date:9/20/2014)... CA (PRWEB) September 20, 2014 On ... receive a $250,000 pediatric cancer research grant from Hyundai ... Loma Linda University Children’s Hospital located on 11234 Anderson ... work of Dr. Kimberley Payne, Associate Professor at Loma ... work focuses on leukemia in children. , ...
Breaking Medicine News(10 mins):Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 3Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 2Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3
... Even when treated with hormone therapy to suppress ... their prostate cancer worsening, researchers at Duke University Medical ... American Urological Association annual meeting Sunday (May 15, 2011), ... has generated research interest in recent years as the ...
... May 14 (HealthDay News) -- There appears to be a ... exposed to the herbicide in Vietnam, a new study suggests. ... La. examined the records of 297 patients diagnosed with kidney ... 39 to 63 when they were diagnosed, said they had ...
... Continuous positive airway pressure, or CPAP, can increase ... of obstructive sleep apnea (OSA), even if their symptoms ... in Europe. Patients enrolled in the study reported an ... CPAP treatment. The study will be presented at ...
... airway pressure (CPAP) effectively decreases the risk of cardiovascular ... apnea (OSA), according to a study conducted by researchers ... to assess the impact of OSA and the effectiveness ... The findings will be presented at the ATS ...
... Hospital patients with pneumonia may be at risk ... no warning signs, according to research from the University ... American Heart Association,s Get with the Guidelines project. ... the American Thoracic Society,s 2011 International Conference in Denver. ...
... News) -- A program to boost heart health in students at ... expanded to about 20 middle schools in the state, researchers say. ... to: Eat more fruits and vegetables , Eat ... 150 minutes of physical activity a week , Spend less time ...
Cached Medicine News:Health News:Obesity linked to higher risk of prostate cancer progression 2Health News:Agent Orange Linked to Kidney Cancer: Study 2Health News:CPAP improves daytime sleepiness even in patients with low levels of symptoms 2Health News:CPAP decreases cardiovascular mortality in elderly patients 2Health News:CPAP decreases cardiovascular mortality in elderly patients 3Health News:Pneumonia patients at risk for in-hospital cardiac arrest 2Health News:Teaching Kids to Make Healthier Choices May Pay Off 2
Silver Aluminum finish, full view tempered bent glass sides and door 2 sliding glass doors with push bottom lock and 4 adjustable shelves. Pearwood MDF roof and base. Roof with 3 50 watt recessed hal...
Two sided, 72 frame, acrylic eyewear tower with side mirrors and sign holder on top. Breaks down for easy shipping....
1 Frame clear base post with transparent Eyevee 2.0 Clip....
Omni labs carries an extensive line of frames, lenses, soft contacts, RGP lenses, and many other products and services. It supports Zeiss, American optical, Sola, Rodenstock, Zylowear, Eyewear design...
Medicine Products: